Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer
Authors
Keywords
-
Journal
Future Oncology
Volume 16, Issue 3, Pages 4439-4453
Publisher
Future Medicine Ltd
Online
2019-12-12
DOI
10.2217/fon-2019-0468
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunotherapy and targeted therapy combinations in metastatic breast cancer
- (2019) Francisco J Esteva et al. LANCET ONCOLOGY
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
- (2019) Chrétien et al. Cancers
- Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice
- (2019) Andreas Schneeweiss et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- 5-year results for pembrolizumab treatment of advanced melanoma
- (2019) Jessica C Hassel LANCET ONCOLOGY
- Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
- (2018) D A Yardley et al. ANNALS OF ONCOLOGY
- JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer
- (2018) Meixuan Chen et al. Clinical Breast Cancer
- Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
- (2018) Elisa Gobbini et al. EUROPEAN JOURNAL OF CANCER
- Olaparib for the treatment of breast cancer
- (2018) Gaia Griguolo et al. Expert Review of Anticancer Therapy
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
- (2018) Daniel L. Suzman et al. LIVER INTERNATIONAL
- Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
- (2018) Yoh Zen et al. MODERN PATHOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer
- (2018) Aurélie S. Cazet et al. Nature Communications
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
- (2018) Julie R. Brahmer et al. Journal of Oncology Practice
- Immunological differences between primary and metastatic breast cancer
- (2018) B Szekely et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives
- (2018) Carlo Fremd et al. Expert Review of Anticancer Therapy
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
- (2018) Colt A. Egelston et al. Nature Communications
- Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up
- (2018) Sylvia Adams et al. JAMA Oncology
- Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
- (2018) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
- (2017) Nobumoto Tomioka et al. Breast Cancer
- Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review
- (2016) M.N Joshi et al. CLINICAL ENDOCRINOLOGY
- Prognostic significance of PD-L1 and PD-L2 in breast cancer
- (2016) Mauricio Z. Baptista et al. HUMAN PATHOLOGY
- Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
- (2016) Hidenori Mizugaki et al. INVESTIGATIONAL NEW DRUGS
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
- (2016) Jonathan L. Curry et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor
- (2016) Rong Deng et al. mAbs
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
- (2016) Sasha E. Stanton et al. JAMA Oncology
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature
- (2015) Simon B. Zeichner et al. BREAST CANCER RESEARCH AND TREATMENT
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab
- (2015) Tomohiko Narita et al. JOURNAL OF DERMATOLOGY
- Natural and therapy-induced immunosurveillance in breast cancer
- (2015) Guido Kroemer et al. NATURE MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
- (2015) Tao Qin et al. Oncotarget
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
- (2014) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
- (2014) Miguel F. Sanmamed et al. CANCER JOURNAL
- Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
- (2014) A. R. de Biasi et al. CLINICAL CANCER RESEARCH
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
- (2014) K. A. Schalper et al. CLINICAL CANCER RESEARCH
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
- (2014) Yanping Xiao et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ipilimumab in patients with cancer and the management of dermatologic adverse events
- (2014) Mario E. Lacouture et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
- (2013) D. W. Miles et al. ANNALS OF ONCOLOGY
- Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer
- (2013) D. Alizadeh et al. CANCER RESEARCH
- Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study
- (2013) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
- (2013) Sherene Loi OncoImmunology
- Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
- (2012) Nancy U. Lin et al. CANCER
- Suppression, subversion and escape: the role of regulatory T cells in cancer progression
- (2012) K. Oleinika et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- A Guide to Rational Dosing of Monoclonal Antibodies
- (2012) Shuang Bai et al. CLINICAL PHARMACOKINETICS
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2011) Adam M. Brufsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions
- (2009) O Akbari et al. Mucosal Immunology
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma
- (2007) Koichiro Matsumoto et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started